The global market for clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a compound annual growth rate (CAGR) of 31.4% for the period of 2020-2025.
Report Scope
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2019, 2020 and 2025.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health and transplant medicine.
Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the rest of the world.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct to consumer testing; and noninvasive prenatal testing.
More than 200 companies in the clinical NGS industry are profiled in this report.
The report provides a summary of the main industry acquisitions and strategic alliances from January 2019 through April 2021, including key alliance trends.
The Report Includes
- 29 data tables and 73 additional tables
- An updated review of the global market for emerging clinical applications of the next-generation sequencing (NGS) based diagnostics and related technologies
- Analyses of the global market trends, with data from 2019-2020, and projections of compound annual growth rates (CAGRs) through 2025
- Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenario, and penetration of NGS-based diagnostics and technologies within the industry
- Estimation of the current market size and revenue forecasts for the global NGS diagnostic markets, and corresponding market share analysis by disease indication, test complexity, test purpose, application and geographic region
- Evaluation of the key NGS workflow portions of the industry (e.g., sequencing instruments, pre-sequencing target preparation and capture, and post-sequencing data analysis) and the main clinical indications where NGS will capture significant market share by 2025
- Assessment of main sequencing technologies and explanation of the importance of genetic variation in clinical testing as well as some of the significant research initiatives affecting clinical NGS applications
- A summary of the major acquisitions and strategic alliances in the clinical NGS industry from January 2019 through April 2021, including key alliance trends
- Patent review and significant allotments of the U.S. patents in the liquid biopsy industry
- Company profiles of the major market players, including Agilent Technologies Inc., Becton, Dickinson and Co. (BD), Koninklijke Philips N.V., Merck KGaA, Novogene Co. Ltd., Oxford Nanopore Technologies Ltd., Qiagen NV, Roche Holding AG, and Thermo Fisher Scientific Inc.
What is the estimated value of the Global Next-generation Sequencin Market?
What is the growth rate of the Global Next-generation Sequencin Market?
What is the forecasted size of the Global Next-generation Sequencin Market?
Who are the key companies in the Global Next-generation Sequencin Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 417 |
| Published | May 2021 |
| Forecast Period | 2020 - 2025 |
| Estimated Market Value ( USD | $ 5.9 Billion |
| Forecasted Market Value ( USD | $ 22.9 Billion |
| Compound Annual Growth Rate | 31.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 206 |
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- Related Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Introduction
- Liquid and Tissue Biopsy
- Clinical NGS Testing Market
- Growth Drivers of Clinical NGS
- Key Trends
- Industry
Chapter 4 Technology Background
- Importance of DNA
- Genetic Variation and Analysis
- Genetic Analysis Technologies
- Sequencing in Clinical Applications
- Sequencing Technologies
- History of DNA Sequencing
- Sanger Sequencing Technology
- NGS Platforms
- Short-Read Platforms
- Long-Read Platforms
- Informatics Technologies
- Base Calling
- Mapping to a Reference Sequence
- Variant Analysis
- Artificial Intelligence Technologies
- Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives
- R&D Initiatives and Programs
- 1+ Million Genomes
- Access to Treatment and Testing (ACTT)
- Access to Comprehensive Genomic Profiling Coalition (ACGP)
- Africa Pathogen Genomics Initiative
- Blood Profiling Atlas
- Cancer-ID
- Cancer Moon Shots Program
- China Precision Medicine Initiative
- ClinGen
- CTC Trap Consortium
- diaRNAgnosis Project
- Early Cancer Detection Consortium
- EpiFemCare
- France Genomic Medicine Plan
- Friends of Cancer Research Project
- Genomic Medicine Sweden
- HCA-Organoid
- Human Cell Atlas
- Human Immunomics Initiative
- Immunomonitor Consortium
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
- Intervene
- Liquid Biopsies and Imaging for Improved Cancer Care
- Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
- Liver Cancer Early Screening Comprehensive Prevention and Control Project
- Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
- Million Veteran Program
- Medical Genome Initiative
- MedSeq
- Precision Medicine Initiative
- Prompt
- QuIP Project
- SPHERES
- Target ALS Diagnosis Initiative
- TopMed
- Treehouse Childhood Cancer Initiative
- Very Rare Cancer Consortium
- Worldwide Innovative Networking (WIN) Consortium
- Single-Cell Research
- Cambridge Single-Cell Analysis Core Facility
- Harvard Medical School Single-Cell Core
- Mayo Medical Genome Facility
- National Center for Single-Cell Biology
- Next-Generation Single-Cell Analysis Program
- Single-Cell Analysis Core
- UC San Francisco Single-Cell Analysis Center
- Population Sequencing Projects
Chapter 6 Clinical NGS Applications
- Introduction
- Cancer Applications
- Precision Medicine
- Liquid Biopsy Biomarkers
- Mendelian Disorders Applications
- Reproductive Health Applications
- Noninvasive Prenatal Testing
- Newborn Screening
- Microbiology and Infectious Disease Applications
- Complex Disorders Applications
Chapter 7 Clinical NGS Industry
- Sequencing Instrument Industry
- Companies
- Third-Generation Sequencing Industry
- Sequencing Informatics Industry
- Target Enrichment and Amplification Industry
- CTC Capture and Detection Industry
- Liquid Biopsy Assay Industry
- Liquid Biopsy Cancer Screening/Early Detection Industry
- Health-Focused DTC Genetic Testing Industry: Two Market Models
- DTC Clinical Health Genetic Testing Industry
- Noninvasive Prenatal Testing (NIPT) Industry
Chapter 8 Acquisitions and Strategic Alliances
- Acquisitions
- Strategic Alliances
- Key Trends
Chapter 9 Clinical NGS Markets
- Market Dynamics
- Market Drivers
- Impact of COVID-19 on the Clinical NGS Markets
- Clinical NGS Market by Disease Category
- Oncology
- Cardiology
- NGS Mendelian Disorders
- Metabolic/Immune Disorders
- Neurology
- Reproductive Health
- Microbiology and Infectious Diseases
- Transplantation
- Geographical Markets
- Global Market for NGS in Oncology by Region
- Global Market for NGS in Reproductive Health by Region
Chapter 10 Patent Review
- Patents on Circulating Tumor Cells
- Patents on Exosomes
- Patents on Cell-Free DNA
- Patents Related to Biomarkers
- Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
- Liquid Biopsy Patent Litigation
Chapter 11 Company Profiles
- Accuragen Inc.
- Adaptive Biotechnologies Inc.
- Agilent Technologies Inc.
- Alcediag
- Ambry Genetics
- Amoy Diagnostics Co. Ltd.
- Angle Plc
- Apocell Inc.
- Apostle Inc.
- Arcedi Biotech Aps
- Archer Dx
- Armonica Technologies Inc.
- Arup Laboratories
- Asuragen Inc.
- Aviva Biomed Inc.
- Aviva Biosciences
- Bard1 Life Sciences Ltd.
- Base Genomics
- Baylor Genetics
- Becton, Dickinson And Co.
- Berry Genomics Co. Ltd.
- BGI Shenzhen
- Biocaptiva Ltd.
- Biocept Inc.
- Biodesix Inc.
- Biofluidica Inc.
- Biolidics Ltd.
- Biological Dynamics Inc.
- Bionano Genomics
- Bio-Techne Corp.
- Bitbiome, Inc.
- Bluestar Genomics Inc.
- Burning Rock Biotech Ltd.
- C2I Genomics
- Cambridge Epigenetix
- Cancer Genetics Inc.
- Canexia Health
- Capio Biosciences
- Captis Diagnostics Inc.
- Caredx Inc.
- Caris Life Science
- Cegat Gmbh
- Cellmax Life
- Cell Microsystems Inc.
- Celsee Diagnostics
- Centrillion Genomics Technologies
- Chronix Biomedical
- Circulogene Theranostics
- Claret Bioscience
- Clinical Genomics Technologies
- Codiak Biosciences
- Cogenica
- Cradle Genomics
- Cyclomics
- Cygnus Biosciences Co. Ltd.
- Cytotrack Aps
- Danaher Corp.
- Dante Labs
- Datar Cancer Genetics Ltd.
- Delfi Diagnostics
- Diacarta Inc.
- Diagnologix Llc
- Diagnomics
- Diamir Bio
- Dnalytics
- Dnanexus Inc.
- Dovetail Genomics Llc
- Earlydx Inc.
- Eone-Diagnomics Genome Center
- Encrypgen
- Epic Sciences Inc.
- Epigenomics Ag
- Eurofins Scientific
- Exact Sciences Corp.
- Exosome Sciences Inc.
- Exosomics Spa
- Exopert
- Ezlife Bio Inc.
- Fabric Genomics
- Fluxion Biosciences Inc.
- Freenome Inc.
- Fulgent Genetics Inc.
- Full Genomes Corp. Inc.
- Genapsys Inc.
- Gene By Gene Ltd.
- Genedx Inc.
- Genetron Health Technologies
- Geneseq Biosciences Pty Ltd.
- Genexosome Technologies Inc.
- Genomictree
- Genomoncology
- Genosaber
- Genosity
- Grail Inc.
- Guardant Health Inc.
- Helio Health
- Helix Opco Llc
- Hitgen
- Htg Molecular Diagnostics Inc.
- Id Solutions
- Illumina Inc.
- Incelldx Inc.
- Inex Innovate Pte. Ltd.
- Inivata Ltd.
- Insitome Inc.
- Interpace Biosciences Inc.
- Invitae Inc.
- Invivoscribe Inc.
- Jabrehoo Medtech Co., Ltd.
- Jbs Science Inc.
- Jumpcode Genomics Inc.
- Koninklijke Philips N.V.
- Laboratory Corp. Of America Inc.
- Labgenomics Co., Ltd.
- Labrinth Biotech Inc.
- Lariat Biosciences Inc.
- Liquid Biopsy Labs
- Lucence Diagnostics Pte. Ltd.
- Lunglife Ai Inc.
- Macrogen Inc.
- Mapmygenome
- Mdxhealth Inc.
- Medgenome Inc.
- Menarini Silicon Biosystems Spa
- Merck Kgaa
- Micareo Rare Cell Diagnostics
- Micronoma
- Mir Scientific
- Mutantdx
- Myriad Genetics Inc.
- Namocell Inc.
- Nanostring Technologies Inc.
- Nanoview Biosciences Inc.
- Natera Inc.
- Nebula Genomics
- Neogenomics Laboratories
- Neo New Oncology Gmbh
- New England Biolabs
- New Horizon Health Ltd.
- Nipd Genetics
- Novigenix Sa
- Novogene Co. Ltd.
- Nrichdx Inc.
- Nuprobe Inc.
- Nx Prenatal Inc.
- Oncimmune Holdings Plc
- Oncocyte Corp.
- Oncodna S.A.
- Opko Health
- Orchid Health Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences Of California Inc.
- Pangaea Oncology
- Personal Genome Diagnostics Inc.
- Personalis Inc.
- Pfdena Inc.
- Phase Scientific
- Phosphorus Inc.
- Pieriandx
- Pwnhealth
- Predicine Inc.
- Prenetics Group
- Qcdx Llc
- Qiagen Nv
- Quantapore Inc.
- Quantgene Inc.
- Quantum Biosystems Inc.
- Quantumdx
- Quest Diagnostics Inc.
- Rarecells Sas
- Ravgen
- Real Time Genomics Inc.
- Resolution Bioscience Inc.
- Roche Holding Ag
- Saga Diagnostics Ab
- Sano Genetics
- Sanomics Ltd.
- Screencell
- Seekin
- Seracare Life Sciences Inc.
- Sequencing.Com
- Seven Bridges Genomics Inc.
- Single Technologies
- Singlera Genomics Inc.
- Smartcactch
- Stage Zero Life Sciences
- Strand Life Sciences Pvt. Ltd.
- Strata Oncology
- Stratos Genomics Inc.
- Syapse
- Sysmex Inostics Gmbh
- Tailai Biosciences Co., Ltd.
- Takara Bio Inc.
- Telexos Gmbh
- Thermo Fisher Scientific Inc.
- Twinstrand Biosciences
- Twist Bioscience
- Ubiquity Genomics Inc.
- Universal Diagnostics Sl
- Vela Diagnostics
- Veracyte
- Volitionrx
- Vortex Biosciences
- Xing Technologies Llc
- Yourgene Health Plc
- Yikon Genomics Co. Ltd.
List of Tables
Summary Table: Global Market for Clinical Next-Generation Sequencing, by Disease Class, Through 2025
Table 1: Scope of the Report
Table 2: Global Market for Clinical NGS Testing, by Disease Type, Through 2025
Table 3: Forces Influencing Growth in the Clinical NGS Testing Market
Table 4: Key Trends in the Clinical NGS Testing Market
Table 5: Clinical NGS Industry Subsectors
Table 6: DNA Chemical Building Blocks
Table 7: DNA Translation and Transcription
Table 8: Long-Range DNA Structure
Table 9: Genetic Variant Types
Table 10: Molecular Diagnostic Technology Platforms
Table 11: Genome Coverage of PCR, Microarray and NGS Technology Platforms
Table 12: Genetic Testing Coverage
Table 13: Key Near- to Mid-Term Segments of NGS Diagnostics
Table 14: DNA Sequencing Historical Timeline
Table 15: Sequencing Technology Development, 1990-2020
Table 16: Cost of Sequencing a Single Human Genome, 2001-2021
Table 17: Summary of Sanger Sequencing
Table 18: Improvements in Sanger Sequencing
Table 19: NGS Technologies
Table 20: Illumina NGS Workflow
Table 21: Thermo Fisher Scientific NGS Workflow
Table 22: NGS Bioinformatics Workflow
Table 23: Sequence Annotation Steps
Table 24: Types of AI in Healthcare
Table 25: Future Challenges in Implementing Clinical NGS
Table 26: Clinical NGS Research and Development Initiatives and Programs
Table 27: Single-Cell Core Research Facilities
Table 28: Population Sequencing Projects
Table 29: Clinical NGS Near- to Mid-term Applications
Table 30: Personalized Medicine Driven, by Common Cancer Genetic Mutations
Table 31: Liquid Biopsy Biomarkers
Table 32: NGS-Based Cancer Diagnostics Market Segments
Table 33: Mendelian Disorders Applications
Table 34: Reproductive Health Screening Applications
Table 35: Ethical Issues Associated with NIPT
Table 36: Microbiology/Infectious Disease Applications
Table 37: Complex Disorders Applications
Table 38: Key Segments and Trends in the Clinical NGS Industry
Table 39: NGS and 3GS Industry Company Positioning
Table 40: Long-Read Sequencing Industry
Table 41: Sequencing Informatics Industry
Table 42: NGS Target Enrichment Industry
Table 43: CTC Separations Industry
Table 44: Liquid Biopsy Assay Industry: Company Focus
Table 45: Examples of NGS-Based Liquid Biopsy Market Differentiation
Table 46: Multi-Cancer Screening Test Desired Features
Table 47: Shed Rates of Various Cancers
Table 48: Cancer Screening Liquid Biopsy Industry
Table 49: Thrive Earlier Detection (Exact Sciences) Cancer Targets
Table 50: Colorectal Cancer Early Detection/Screening Liquid Biopsy Industry
Table 51: Key Clinical Trials on Single- and Multi-Cancer Liquid Biopsy Assays
Table 52: Clinical-Grade Health DTC Genetic Testing Companies
Table 53: NIPT Industry
Table 54: Clinical NGS Industry Acquisitions, January 2019–April 2021
Table 55: Strategic Alliances in Clinical NGS, January 2019–April 2021
Table 56: Key Forces Driving Growth in Clinical NGS and Their Implications
Table 57: Global Market for Clinical Sequencing, by Disease Category, Through 2025
Table 58: Global Market for Clinical NGS, by Test Complexity, Through 2025
Table 59: Global Market for Clinical NGS, by Purpose of Test, Through 2025
Table 60: Limitations of Tissue Biopsy in Cancer Applications
Table 61: Low-Frequency Mutation Detection
Table 62: Global Market for Clinical NGS in Oncology, by Indication, Through 2025
Table 63: Five-Year Survival Rate for Ovarian Cancer
Table 64: National Institutes of Health Liquid Biopsy Early Detection Initiative
Table 65: Clinical Trials on Lung Cancer Liquid Biopsies
Table 66: Global Market for Clinical NGS in Oncology, by Purpose of Test, Through 2025
Table 67: MRI and Liquid Biopsy Methods
Table 68: Early Detection Tissue of Origin Approaches
Table 69: Global Market for Clinical NGS in Oncology, by Test Complexity, Through 2025
Table 70: European Society of Medical Oncology NGS Recommendations for Metastatic Cancers, August 2020
Table 71: Global Market for Clinical NGS in Cardiology Diagnostics, by Purpose of Test, Through 2025
Table 72: NGS-Based Dilated Cardiomyopathy Test Providers
Table 73: Global Market for Clinical NGS in Cardiology Diagnostics, by Test Complexity, Through 2025
Table 74: Global Market for Clinical NGS in Mendelian Disorder Diagnostics, by Purpose of Test, Through 2025
Table 75: Global Market for Clinical NGS in Mendelian Disorder Diagnostics, by Test Complexity, Through 2025
Table 76: Global Market for Clinical NGS in Metabolic and Immune Disorder Diagnostics, by Purpose of Test, Through 2025
Table 77: Multiple Sclerosis Diagnostic Technologies
Table 78: Global Market for Clinical NGS in Metabolic and Immune Disorder Diagnostics, by Test Complexity, Through 2025
Table 79: Global Market for Clinical NGS in Neurological Diagnostics, by Purpose of Test, Through 2025
Table 80: Global Market for Clinical NGS in Neurological Diagnostics, by Test Complexity, Through 2025
Table 81: Global Market for Clinical NGS in Reproductive Health, by Application, Through 2025
Table 82: Global NGS-Based NIPT Market, by Risk Type, Through 2025
Table 83: Global Market for Clinical NGS in Reproductive Health, by Purpose of Test, Through 2025
Table 84: Global Market for Clinical NGS in Reproductive Health, by Test Complexity, Through 2025Global Market for Clinical NGS in Reproductive Health, by Test Complexity, Through 2025
Table 85: NGS-Based Infectious Disease Landscape
Table 86: Global Market for Clinical NGS-Based Microbiology and Infectious Disease Diagnostics, by Purpose of Test, Through 2025
Table 87: Global Market for Clinical NGS-Based Microbiology and Infectious Disease Diagnostics, by Test Complexity, Through 2025
Table 88: NGS in Infectious Disease Diagnostics
Table 89: Global Market for Clinical NGS in Transplantations, by Organ, Through 2025
Table 90: Transplant Procedures Performed in the U.S., by Organ, 2018-2020
Table 91: Global Market for Clinical NGS in Transplantation, by Purpose of Test, Through 2025
Table 92: Global Market for Clinical NGS in Transplantation, by Test Complexity, Through 2025
Table 93: Global Market for Clinical NGS, by Region, Through 2025
Table 94: Global Market for Clinical NGS in Oncology, by Region, Through 2025
Table 95: Global Market for NGS in Reproductive Health, by Region, Through 2025
Table 96: Global Market for Clinical NGS in Transplantation, by Region, Through 2025
Table 97: Patent Activity on Circulating Tumor Cells (CTCs), by Country/Region, January 2010–June 2020
Table 98: Patent Activity on Exosomes, by Country/Region, January 2010–December 2020
Table 99: Patent Activity on Cell-Free DNA, by Country/Region, January 2010–December 2020
Table 100: Patent Activity on Cancer Biomarkers, by Country/Region, January 2010–December 2020
Table 101: Status of NGS-Based Liquid Biopsy Patent Disputes
List of Figures
Summary Figure: Global Market for Clinical Next-Generation Sequencing, by Disease Class, 2019-2025
Executive Summary
Next-generation sequencing (NGS) has emerged as an essential technology in clinical diagnostics. This rise to prominence is due to many factors, among which include the following:
- The growing use of precision medicine to treat diseases.
- Demonstration of clinical utility in large-scale prospective clinical trials.
- A steady decrease in sequencing costs.
- Emerging use of liquid biopsy formats.
Several unique aspects of NGS make it a desirable technology for clinical applications. Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.
NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase pregnancy success rates in in-vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis.
The NGS platform allows companies to expand the menu of disorders/diseases overtime after the initial launch of a test. This strategy has been employed in reproductive health applications, for example, launching a test to initially screen for aneuploidies, and then later expanding the test to include screening for additional genetic variants.
These features of NGS platforms provide a solid basis for the use of this technology in the clinic.
Companies Mentioned
- Accuragen Inc.
- Adaptive Biotechnologies Inc.
- Agilent Technologies Inc.
- Alcediag
- Ambry Genetics
- Amoy Diagnostics Co. Ltd.
- Angle Plc
- Apocell Inc.
- Apostle Inc.
- Arcedi Biotech Aps
- Archer Dx
- Armonica Technologies Inc.
- Arup Laboratories
- Asuragen Inc.
- Aviva Biomed Inc.
- Aviva Biosciences
- Bard1 Life Sciences Ltd.
- Base Genomics
- Baylor Genetics
- Becton, Dickinson And Co.
- Berry Genomics Co. Ltd.
- Bgi Shenzhen
- Bio-Techne Corp.
- Biocaptiva Ltd.
- Biocept Inc.
- Biodesix Inc.
- Biofluidica Inc.
- Biolidics Ltd.
- Biological Dynamics Inc.
- Bionano Genomics
- Bitbiome, Inc.
- Bluestar Genomics Inc.
- Burning Rock Biotech Ltd.
- C2I Genomics
- Cambridge Epigenetix
- Cancer Genetics Inc.
- Canexia Health
- Capio Biosciences
- Captis Diagnostics Inc.
- Caredx Inc.
- Caris Life Science
- Cegat Gmbh
- Cell Microsystems Inc.
- Cellmax Life
- Celsee Diagnostics
- Centrillion Genomics Technologies
- Chronix Biomedical
- Circulogene Theranostics
- Claret Bioscience
- Clinical Genomics Technologies
- Codiak Biosciences
- Cogenica
- Cradle Genomics
- Cyclomics
- Cygnus Biosciences Co. Ltd.
- Cytotrack Aps
- Danaher Corp.
- Dante Labs
- Datar Cancer Genetics Ltd.
- Delfi Diagnostics
- Diacarta Inc.
- Diagnologix Llc
- Diagnomics
- Diamir Bio
- Dnalytics
- Dnanexus Inc.
- Dovetail Genomics Llc
- Earlydx Inc.
- Encrypgen
- Eone-Diagnomics Genome Center
- Epic Sciences Inc.
- Epigenomics Ag
- Eurofins Scientific
- Exact Sciences Corp.
- Exopert
- Exosome Sciences Inc.
- Exosomics Spa
- Ezlife Bio Inc.
- Fabric Genomics
- Fluxion Biosciences Inc.
- Freenome Inc.
- Fulgent Genetics Inc.
- Full Genomes Corp. Inc.
- Genapsys Inc.
- Gene By Gene Ltd.
- Genedx Inc.
- Geneseq Biosciences Pty Ltd.
- Genetron Health Technologies
- Genexosome Technologies Inc.
- Genomictree
- Genomoncology
- Genosaber
- Genosity
- Grail Inc.
- Guardant Health Inc.
- Helio Health
- Helix Opco Llc
- Hitgen
- Htg Molecular Diagnostics Inc.
- Id Solutions
- Illumina Inc.
- Incelldx Inc.
- Inex Innovate Pte. Ltd.
- Inivata Ltd.
- Insitome Inc.
- Interpace Biosciences Inc.
- Invitae Inc.
- Invivoscribe Inc.
- Jabrehoo Medtech Co., Ltd.
- Jbs Science Inc.
- Jumpcode Genomics Inc.
- Koninklijke Philips N.V.
- Labgenomics Co., Ltd.
- Laboratory Corp. Of America Inc.
- Labrinth Biotech Inc.
- Lariat Biosciences Inc.
- Liquid Biopsy Labs
- Lucence Diagnostics Pte. Ltd.
- Lunglife Ai Inc.
- Macrogen Inc.
- Mapmygenome
- Mdxhealth Inc.
- Medgenome Inc.
- Menarini Silicon Biosystems Spa
- Merck Kgaa
- Micareo Rare Cell Diagnostics
- Micronoma
- Mir Scientific
- Mutantdx
- Myriad Genetics Inc.
- Namocell Inc.
- Nanostring Technologies Inc.
- Nanoview Biosciences Inc.
- Natera Inc.
- Nebula Genomics
- Neo New Oncology Gmbh
- Neogenomics Laboratories
- New England Biolabs
- New Horizon Health Ltd.
- Nipd Genetics
- Novigenix Sa
- Novogene Co. Ltd.
- Nrichdx Inc.
- Nuprobe Inc.
- Nx Prenatal Inc.
- Oncimmune Holdings Plc
- Oncocyte Corp.
- Oncodna S.A.
- Opko Health
- Orchid Health Inc.
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences Of California Inc.
- Pangaea Oncology
- Personal Genome Diagnostics Inc.
- Personalis Inc.
- Pfdena Inc.
- Phase Scientific
- Phosphorus Inc.
- Pieriandx
- Predicine Inc.
- Prenetics Group
- Pwnhealth
- Qcdx Llc
- Qiagen Nv
- Quantapore Inc.
- Quantgene Inc.
- Quantum Biosystems Inc.
- Quantumdx
- Quest Diagnostics Inc.
- Rarecells Sas
- Ravgen
- Real Time Genomics Inc.
- Resolution Bioscience Inc.
- Roche Holding Ag
- Saga Diagnostics Ab
- Sano Genetics
- Sanomics Ltd.
- Screencell
- Seekin
- Sequencing.Com
- Seracare Life Sciences Inc.
- Seven Bridges Genomics Inc.
- Single Technologies
- Singlera Genomics Inc.
- Smartcactch
- Stage Zero Life Sciences
- Strand Life Sciences Pvt. Ltd.
- Strata Oncology
- Stratos Genomics Inc.
- Syapse
- Sysmex Inostics Gmbh
- Tailai Biosciences Co., Ltd.
- Takara Bio Inc.
- Telexos Gmbh
- Thermo Fisher Scientific Inc.
- Twinstrand Biosciences
- Twist Bioscience
- Ubiquity Genomics Inc.
- Universal Diagnostics Sl
- Vela Diagnostics
- Veracyte
- Volitionrx
- Vortex Biosciences
- Xing Technologies Llc
- Yikon Genomics Co. Ltd.
- Yourgene Health Plc
